Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued ...
Cumulative culture -- the accumulation of technological modifications and improvements over generations -- allowed humans to adapt to a diversity of environments and challenges. But, it is unclear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results